Krebs Biochemicals & Industries Limited

KREBSBIO

INE268B01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:58 05/07/2024 pm IST			5-day change	1st Jan Change
72.9 ^INR	+2.23%		+3.30%	-6.94%

21/05	Krebs Biochemicals & Industries Limited Appoints Rakesh Kalbate as Company Secretary/Compliance Officer	CI
21/05	Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Krebs Biochemicals & Industries Limited Reports Earnings Results for the Full Year Ended March 31, 2020

September 01, 2020 at 10:59 pm IST

Krebs Biochemicals & Industries Limited announced earnings results for the full year ended March 31, 2020. For the full year, the company announced total revenue was INR 337.773 million compared to INR 480.886 million a year ago. Net loss was INR 288.72 million compared to INR 200.115 milliona year ago.

Latest news about Krebs Biochemicals & Industries Limited

Krebs Biochemicals & Industries Limited Appoints Rakesh Kalbate as Company Secretary/Compliance Officer	21/05	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	21/05	CI
Krebs Biochemicals & Industries Limited Announces Resignation of Keyur Doshi as Company Secretary, Compliance Officer	15/04	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer	17/01	CI
Andhra Pradesh Pollution Control Board Orders Production Halt at Krebs Biochemicals Plant	18/12	MT
Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer	20/23/20	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/23/09	CI
Krebs Biochemicals & Industries Limited Approves Resignation of Mr. Pabitrakumar Kalipada Bhattacharya as Managing Director	09/23/09	CI
Krebs Biochemicals Limited Announces Executive Changes, Effective 10 August 2023	09/23/09	CI
Krebs Biochemicals Trims Net Loss in Fiscal Q4	24/23/24	MT
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	24/23/24	CI
Krebs Biochemicals Names New CFO	03/23/03	MT
Krebs Biochemicals & Industries Limited Approves Appointment of Rohit Taparia as Company Secretary and Compliance Officer	03/23/03	CI
Krebs Biochemicals & Industries Limited Approves CFO Changes	03/23/03	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/22/10	CI
Krebs Biochemicals & Industries Limited Auditor Raises 'Going Concern' Doubt	06/22/06	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	01/22/01	CI
Taruni Banda Resigns as Company Secretary and Compliance Officer of Krebs Biochemicals & Industries Limited, Effective from August 6, 2022	01/22/01	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	23/22/23	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	12/22/12	CI
Krebs Biochemicals & Industries Limited announced that it has received INR 1 billion in funding from Ipca Laboratories Limited	30/21/30	CI
Krebs Biochemicals & Industries Limited Appoints Jitendra Shah as Additional Director, Non-Executive Category	09/21/09	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	09/21/09	CI
Krebs Biochemicals & Industries Limited to Consider Resignation of E J Babu as Non-Executive Director	02/21/02	CI

Chart Krebs Biochemicals & Industries Limited

Duration

Period

Chart Krebs Biochemicals & Industries Limited

More charts

Company Profile

Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Companyâs pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KREBS BIOCHEMICALS & INDUSTRIES LIMITED	-6.94%	18.83M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+24.53%	45.07B
OTSUKA HOLDINGS CO., LTD.	+30.99%	23.39B
SANDOZ GROUP AG	+24.13%	16.08B
CIPLA LIMITED	+21.15%	14.6B
ZYDUS LIFESCIENCES LIMITED	+68.67%	14.01B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-13.29%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.53%	5.64B